8 completed, 4 terminated, 3 unknown, 2 recruiting. 20 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 8, Terminated 4, Unknown 3, Recruiting 2, Active not recruiting 1, Suspended 1, Withdrawn 1 |
| Phase 2 | 3 | Active not recruiting 1, Terminated 1, Unknown 1 |
Follow Glioblastoma Multiforme: new trials by email Literature Review of Glioblastoma Multiforme trials Research Report on Glioblastoma Multiforme
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma ICT-107, Placebo - Glioblastoma Multiforme | Phase 3 | Suspended | Precision Life Sciences Group | 234 | 2024-12-01 | 2024-04-03 |
| A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound - Glioblastoma Multiforme, Glioblastoma | Phase 3 | Recruiting | NaviFUS Corporation | 32 | 2024-11-08 | 2026-04-09 |
| Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation, Temozolomide and Radiation Alone - Glioblastoma, Glioblastoma Multiforme | Phase 3 | Recruiting | Northwell Health | 432 | 2022-04-27 | 2026-06-01 |
| LAM561 With RT and TMZ for Adults With Glioblastoma LAM561, TMZ, RT - Primary Glioblastoma, Glioblastoma Multiforme | Phase 2 / Phase 3 | Active not recruiting | Laminar Pharmaceuticals | 144 | 2019-12-01 | 2025-11-20 |
| ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM) Autologous Dendritic Cell/Tumor Antigen, ADCTA - Glioblastoma Multiforme | Phase 3 | Unknown | Safe Save Medical Cell Sciences & Technology Co.,Ltd. | 118 | 2019-09-19 | 2020-03-17 |
| A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Sunitinib, Lomustine - Glioblastoma Multiforme, Glioblastoma, Adult | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 100 | 2018-08-31 | 2021-04-19 |
| UNITE Study: Understanding New Interventions With GBM ThErapy Steroid eye drops, Vasoconstrictor eye drops, Cold compress - Glioblastoma Multiforme | Phase 3 | Terminated | AbbVie | 40 | 2018-07-30 | 2021-04-14 |
| VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM VAL-083, Dianhydrogalactitol, Physician's Choice of Salvage Therapy - temozolomide, Physician's Choice of Salvage Therapy - lomustine - Glioblastoma Multiforme, Glioblastoma | Phase 3 | Terminated | DelMar Pharmaceuticals, Inc. | 2 | 2017-10-27 | 2025-09-04 |
| The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Toca 511, Toca FC, Lomustine - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 2 / Phase 3 | Terminated | Tocagen Inc. | 403 | 2015-11-30 | 2020-02-07 |
| Bevacizumab and Lomustine for Recurrent GBM bevacizumab, lomustine, DNA methylation analysis - Glioblastoma Multiforme, Cognition Disorders | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 592 | 2011-10-01 | 2021-02-15 |
| Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) NovoTTF-100A device, Temozolomide - Glioblastoma Multiforme | Phase 3 | Completed | NovoCure Ltd. | 700 | 2009-06-01 | 2017-04-10 |
| Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Radiotherapy - Glioblastoma Multiforme | Phase 3 | Completed | International Atomic Energy Agency | 115 | 2009-02-01 | 2015-03-24 |
| Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy Neuradiab + Radiotherapy + Temozolomide, Radiation Therapy + Temozolomide - Glioblastoma Multiforme | Phase 3 | Terminated | Bradmer Pharmaceuticals Inc. | 9 | 2008-06-01 | 2011-02-10 |
| Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Dendritic cell immunotherapy - Glioblastoma Multiforme, Glioblastoma | Phase 3 | Unknown | Northwest Biotherapeutics | 348 | 2006-12-01 | 2022-05-18 |
| Chloroquine for Treatment of Glioblastoma Multiforme Chloroquine - Glioblastoma Multiforme | Phase 3 | Completed | National Institute of Neurology and Neurosurgery, Mexico | 2005-01-01 | 2009-11-18 | |
| Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Imatinib mesylate, Hydroxyurea - Glioblastoma Multiforme, Astrocytoma | Phase 3 | Completed | Novartis Pharmaceuticals | 240 | 2004-10-01 | 2011-04-26 |
| Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme TransMID™ - Glioblastoma Multiforme | Phase 3 | Withdrawn | Xenova Biomedix | 323 | 2004-05-01 | 2009-01-07 |
| The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme IL13-PE38QQR, surgery and catheter placement (2 procedures), prolifespan 20 with carmustine implant (GLIADEL® Wafer) - Glioblastoma Multiforme | Phase 3 | Completed | INSYS Therapeutics Inc | 300 | 2004-02-01 | 2011-06-06 |
| Radiotherapy for Malignant Astrocytomas in the Elderly Radiotherapy - Primary Brain Tumor, Anaplastic Astrocytoma | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 2001-02-01 | 2007-02-02 | |
| Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma Conventional RT, Hyperfractionated RT, Carmustine - Glioma, Glioblastoma Multiforme | Phase 3 | Completed | Radiation Therapy Oncology Group | 712 | 1990-11-09 | 2019-11-12 |
Glioblastoma (20) · Brain Neoplasms (11) · Glioma (7) · Astrocytoma (4) · Neoplasms (3) · Adenocarcinoma (1) · Cognition Disorders (1) · Neoplasms, Nerve Tissue (1) · Recurrence (1)
Neoplasms by Histologic Type (20) · Neoplasms, Germ Cell and Embryonal (20) · Neoplasms, Glandular and Epithelial (20) · Neoplasms, Neuroepithelial (20) · Neuroectodermal Tumors (20) · Neoplasms, Nerve Tissue (19) · Neoplasms (17) · Astrocytoma (16) · Glioma (13) · Brain Diseases (11) · Central Nervous System Diseases (11) · Central Nervous System Neoplasms (11) · Neoplasms by Site (11) · Nervous System Diseases (11) · Nervous System Neoplasms (11)
Temozolomide (5) · Bevacizumab (4) · Lomustine (3) · Radiotherapy (3) · Carmustine (2) · Radiation (2) · ABT-414 (1) · Chloroquine (1) · DNA Methylation (1) · Dianhydrogalactitol (1) · Flucytosine (1) · Hydroxyurea (1) · IL13-PE38 (1) · Imatinib Mesylate (1) · Mental Status and Dementia Tests (1)
AbbVie (1) · Amsterdam UMC, location VUmc (1) · Assistance Publique - Hôpitaux de Paris (1) · Bradmer Pharmaceuticals Inc. (1) · DelMar Pharmaceuticals, Inc. (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · INSYS Therapeutics Inc (1) · International Atomic Energy Agency (1) · Laminar Pharmaceuticals (1) · National Institute of Neurology and Neurosurgery, Mexico (1) · NaviFUS Corporation (1) · Northwell Health (1) · Northwest Biotherapeutics (1) · Novartis Pharmaceuticals (1) · NovoCure Ltd. (1)
United States (9) · Canada (6) · Germany (5) · Israel (4) · Netherlands (4) · United Kingdom (4) · France (3) · Australia (2) · Austria (2) · Italy (2) · South Korea (2) · Spain (2) · Taiwan (2) · Argentina (1) · Belarus (1)
David A. Reardon, MD (1) · Elena Fidarova (1) · Eric T. Wong, MD (1) · Florence Keime-Guibert, MD (1) · Frank D. Vrionis, MD, MPH, PhD (1) · Herbert H. Engelhard, MD, PhD (1) · John Boockvar, MD (1) · Julio Sotelo, MD (1) · Linda Liau, M.D. (1) · Manfred Westphal, Prof. MD (1) · Marnix L. Bosch, MBA, PhD (1) · Myra E Van Linde, MD (1) · Nicholas Butowski, M.D. (1)
PMID 15727424, PMID 16520474, PMID 17429084, PMID 21715171, PMID 22847020, PMID 23545055, PMID 26392096, PMID 26670971, PMID 27252174, PMID 27744512, PMID 27799506, PMID 28399638, PMID 29141164, PMID 29260225, PMID 29392280, PMID 29843811, PMID 30506499, PMID 31026557, PMID 32020470, PMID 32691060, PMID 33119048, PMID 34692470, PMID 36394838, PMID 41850328
2017 (1)